Snapshot from Sep 17, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory regulatory approval

Amai Proteins sweelin approved in Israel

Analysis based on 6 articles · First reported Jul 20, 2026 · Last updated Aug 31, 2026

Sentiment
40
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The approval expands Amai Proteins' market access, potentially accelerating adoption of its sweet protein in the food and beverage industry and strengthening its commercial position. This regulatory milestone may positively influence investor sentiment toward the company and the broader alternative sweetener sector, though Amai Proteins is privately held.

Food and Beverage Biotechnology

Amai Proteins, an Israeli food-tech company, announced that the Israeli Ministry of Health has approved its precision-fermented sweet protein sweelin as a novel food ingredient for use in over 25 food and beverage categories. This approval marks the third regulatory clearance for sweelin in less than six months, following approvals from the U.S. United States — Food and Drug Administration (GRAS) and the Singapore — Singapore Food Agency. The company highlights sweelin's ability to reduce sugar by up to 70% while being 3,000 times sweeter than sugar, with published clinical evidence showing no effect on blood glucose, insulin, or GLP-1 levels. CEO Amir Guttman expressed pride in being the first sweet protein approved in Israel and emphasized the commercial milestone. The approval enables Israeli manufacturers to commercialize products containing sweelin, supporting the growing demand for clean-label and GLP-1 friendly products.

priv
Amai Proteins is the developer of sweelin and the primary beneficiary of the Israeli approval, which expands its commercial reach and validates its technology. This third regulatory clearance in six months strengthens its market position and growth prospects.
Importance 100.0 Sentiment 70.0
govactor
The Israeli Ministry of Health granted the approval, authorizing sweelin for use in over 25 food and beverage categories. This action facilitates the introduction of a novel sweetener into the Israeli market.
Importance 80.0 Sentiment 10.0
cnt
Israel becomes the third market to approve sweelin, providing local manufacturers with access to a new sweetening technology. This supports the country's food innovation sector and aligns with health-conscious consumer trends.
Importance 60.0 Sentiment 20.0
govactor
The FDA granted GRAS status to sweelin, a key regulatory approval that preceded the Israeli clearance and is part of the company's global regulatory achievements.
Importance 50.0 Sentiment 10.0
cnt
The United States, through the FDA's GRAS approval, was an earlier market to clear sweelin, contributing to the company's global regulatory momentum. This prior approval is referenced as part of the company's milestones.
Importance 50.0 Sentiment 10.0
cnt
Singapore, via the Singapore — Singapore Food Agency, approved sweelin as a sweetening agent, another earlier regulatory clearance that supports the company's international expansion.
Importance 50.0 Sentiment 10.0
govactor
The Singapore — Singapore Food Agency approved sweelin for use as a sweetening agent, another regulatory milestone that contributed to the company's international market access.
Importance 50.0 Sentiment 10.0
per
Amir Guttman, CEO of Amai Proteins, is the public spokesperson for the company and announced the approval. His leadership is central to the company's commercial strategy and regulatory successes.
Importance 40.0 Sentiment 20.0
Israel close ally ↔ United States Israel views the United States as its most crucial ally, relying heavily on its military, economic, and diplomatic suppo
Israel related ↔ Singapore
United States related ↔ Singapore
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.